Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain, Bowel movement irregularity, Decreased appetite, Herpes zoster, Neuralgia
Clinical narrative: Shingles after the 1st dose/hingles on the right side of myannus and up along my private area.; Urinary Tract Infection after the 1st dose/She confirmed I had a UTI; Nerve pain from the shingles after the 1st dose/I had nerve pain in the whole area where the shingles had been; I started having bad abdominal pain and lost my appetite; lost my appetite/I tried to eat but had little success for about seven days; I had no bowel movement for about a week/My bowel movements were eratic I had diarhea then constipation this went on for about six weeks; This spontaneous case was reported by a physician and describes the occurrence of HERPES ZOSTER (Shingles after the 1st dose/hingles on the right side of myannus and up along my private area.) and URINARY TRACT INFECTION (Urinary Tract Infection after the 1st dose/She confirmed I had a UTI) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029A21A and 045C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by reporter.  Concurrent medical conditions included Food allergy (allergic to Sorgum.), Allergy to plants (allergic to sage.), Rheumatoid arthritis since 1991, Hypertension since 2004, BPH since 2004 and Pain (joint pain and swelling.) since 1991. Concomitant products included TAMSULOSIN for BPH, RAMIPRIL for Hypertension, METHOTREXATE for Pain in joint, HYDROXYCHLOROQUINE SULFATE (HCQS) and FOLIC ACID for Rheumatoid arthritis, METOPROLOL SUCCINATE (METOPROLOL EG [METOPROLOL SUCCINATE]) for Tachycardia.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 17-Mar-2021, the patient experienced HERPES ZOSTER (Shingles after the 1st dose/hingles on the right side of myannus and up along my private area.) (seriousness criterion hospitalization) and URINARY TRACT INFECTION (Urinary Tract Infection after the 1st dose/She confirmed I had a UTI) (seriousness criterion hospitalization). On 20-Mar-2021, the patient experienced ABDOMINAL PAIN (I started having bad abdominal pain and lost my appetite) and DECREASED APPETITE (lost my appetite/I tried to eat but had little success for about seven days). On an unknown date, the patient experienced NEURALGIA (Nerve pain from the shingles after the 1st dose/I had nerve pain in the whole area where the shingles had been) and BOWEL MOVEMENT IRREGULARITY (I had no bowel movement for about a week/My bowel movements were eratic I had diarhea then constipation this went on for about six weeks). The patient was hospitalized from 19-Mar-2021 to 19-Mar-2021 due to HERPES ZOSTER and URINARY TRACT INFECTION. The patient was treated with VALACICLOVIR HYDROCHLORIDE (VALACYCLOVIR HCL) on 19-Mar-2021 for Shingles, at an unspecified dose and frequency; SILVER SULFADIAZINE for Shingles, at an unspecified dose and frequency and CIPROFLOXACIN on 19-Mar-2021 for UTI, at an unspecified dose and frequency. On 15-Jun-2021, HERPES ZOSTER (Shingles after the 1st dose/hingles on the right side of myannus and up along my private area.) and URINARY TRACT INFECTION (Urinary Tract Infection after the 1st dose/She confirmed I had a UTI) had resolved. At the time of the report, NEURALGIA (Nerve pain from the shingles after the 1st dose/I had nerve pain in the whole area where the shingles had been), ABDOMINAL PAIN (I started having bad abdominal pain and lost my appetite), DECREASED APPETITE (lost my appetite/I tried to eat but had little success for about seven days) and BOWEL MOVEMENT IRREGULARITY (I had no bowel movement for about a week/My bowel movements were eratic I had diarhea then constipation this went on for about six weeks) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. However, patient's concomitant medication is a confounder.   This case was linked to MOD-2021-263708 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 22-Jul-2021: Significant Follow-up Reporter type changed, New Event, Medical History, Concomitant Medications and Treatment Medication was updated.second dose information updated. Several previous events deleted.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded. However, patient's concomitant medication is a confounder.